Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Xeljanz Doesn't Improve Radiographic Progression In Psoriatic Arthritis. Does It Matter?

Aug 02 2017

• By Derrick Gingery

FDA entrance sign 2016

Related Content

Janssen's Sirukumab Brings Mortality Imbalance Into FDA Panel Review

Aug 01 2017

User Fee Goal Dates

Feb 07 2017

Pfizer's Xeljanz Is First JAK Positive In PsA But Challenges Ahead

Jun 20 2017

Pfizer's Xeljanz: The Slow Road To Blockbuster Status

May 04 2017

Xeljanz Development Plans Scaled Back By Pfizer

Oct 27 2015

Related Companies

Pfizer Inc.

AbbVie Inc.

Johnson & Johnson

Additional Topics

United States Advisory Committees FDA Regulation Drug Review BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window